Historically, biopharma has developed drugs whose differentiated value would be assessed by regulators, providers and patients. Today, payers are increasingly the arbiters of drug value and develop utilization/coverage and payment policies based on a unique set of criteria.
RE helps craft a clear and persuasive value story with credible support to drive payer adoption